Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics
- PMID: 32168001
- DOI: 10.1097/ICU.0000000000000651
Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics
Abstract
Purpose of review: Local therapeutics play an important role in the management of infectious and noninfectious uveitis (NIU) as well as certain masquerade syndromes. This review highlights the established therapeutics and those under investigation for the management of uveitis.
Recent findings: An injectable long-acting fluocinolone acetonide insert was recently approved by the Food and Drug Administration for the treatment of NIU affecting the posterior segment. Intravitreal methotrexate, sirolimus, and anti-vascular endothelial growth factor (VEGF) agents are being evaluated for efficacy in NIU. Intravitreal foscarnet and ganciclovir are important adjuncts in the treatment of viral retinitis as are methotrexate and rituximab for the management of vitreoretinal lymphoma.
Summary: Local injectable steroids with greater durability are now available for NIU but comparative efficacy to other treatment modalities remains to be determined. Local steroid-sparing immunosuppressive agents are undergoing evaluation for efficacy in NIU as are anti-VEGF agents for uveitic macular edema. Local antivirals may improve outcomes in cases of viral retinitis. Local chemotherapeutics can help induce remission in vitreoretinal lymphoma.
Similar articles
-
Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.Ophthalmology. 2016 Sep;123(9):1940-8. doi: 10.1016/j.ophtha.2016.05.025. Epub 2016 Jul 13. Ophthalmology. 2016. PMID: 27421623 Clinical Trial.
-
Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.Ophthalmology. 2011 Oct;118(10):1916-26. doi: 10.1016/j.ophtha.2011.07.027. Epub 2011 Aug 15. Ophthalmology. 2011. PMID: 21840602 Free PMC article. Clinical Trial.
-
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.Ophthalmology. 2015 Oct;122(10):1967-75. doi: 10.1016/j.ophtha.2015.06.042. Epub 2015 Aug 20. Ophthalmology. 2015. PMID: 26298715 Free PMC article. Clinical Trial.
-
Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.Ophthalmology. 2018 Dec;125(12):1984-1993. doi: 10.1016/j.ophtha.2018.06.015. Epub 2018 Jul 27. Ophthalmology. 2018. PMID: 30060978 Review.
-
Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis.Indian J Ophthalmol. 2025 Jan 1;73(Suppl 1):S37-S46. doi: 10.4103/IJO.IJO_712_24. Epub 2024 Sep 19. Indian J Ophthalmol. 2025. PMID: 39297478 Free PMC article. Review.
Cited by
-
A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - A phase I clinical trial.Front Med (Lausanne). 2022 Oct 17;9:1023224. doi: 10.3389/fmed.2022.1023224. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36325389 Free PMC article.
-
Synergistic Effect of Combined Sub-Tenon Triamcinolone and Intravitreal Anti-VEGF Therapy for Uveitic Macular Edema.Drug Des Devel Ther. 2022 Apr 8;16:1055-1066. doi: 10.2147/DDDT.S353251. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35422612 Free PMC article.
-
Comparative Efficacy and Safety of Advanced Intravitreal Therapeutic Agents for Noninfectious Uveitis: A Systematic Review and Network Meta-Analysis.Front Pharmacol. 2022 Apr 5;13:749312. doi: 10.3389/fphar.2022.749312. eCollection 2022. Front Pharmacol. 2022. PMID: 35450045 Free PMC article.
-
Calculated Drug Concentrations in Currently Available Intravitreal Therapies: Determination of Dilution Factor and Deviation From Recommended Doses.Cureus. 2024 Jul 31;16(7):e65888. doi: 10.7759/cureus.65888. eCollection 2024 Jul. Cureus. 2024. PMID: 39092383 Free PMC article.
-
Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema.Int J Retina Vitreous. 2022 Oct 12;8(1):74. doi: 10.1186/s40942-022-00424-x. Int J Retina Vitreous. 2022. PMID: 36224669 Free PMC article.
References
-
- Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005; 140:509–516.
-
- Abdulaal MR, Abiad BH, Hamam RN. Uveitis in the aging eye: incidence, patterns, and differential diagnosis. J Ophthalmol 2015; 2015:509456.
-
- Salek SS, Leder HA, Butler NJ, et al. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm 2013; 21:257–263.
-
- Sen HN, Vitale S, Gangaputra SS, et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology 2014; 121:2275–2286.
-
- Sallam A, Taylor SR, Habot-Wilner Z, et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol 2012; 90:e323–e325.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials